CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Immunoregulatory mechanisms in the development of Chagas disease: translational applications

Research summary:

Chagas disease caused by Trypanosoma cruzi affects approximately 10 million people in Latin America. Besides, blood transfusion and organ transplantation is a sanitary problem in countries receptors of migrants from endemic areas. Cardiac pathology is the most severe and characteristic manifestation and it is estimated a future incidence of between 6.000 y 30.000 cases of chagasic cardiomyopathy in Spain. Our working hypothesis is that the development of pathology depends on a combination of factors: host genetic background, different parasite infecting capacities with different genetic backgrounds, and the regulatory immune response that will affect the inflammatory and the infective processes. Myeloid-derived suppressor cells (MDSC) expand during infection with virulent strains. Figure 1 summarizes the general suppressive mechanisms of MDSC in contact with T cells. On one hand, MDSC expresses nitric oxide synthase (iNOS) and NADPH oxidase 2 (NOX-2) and produces reactive nitrogen species (RNS) and reactive oxygen species (ROS), respectively. Protein nitration and nitrosylation by RNS lead to apoptosis and inhibition of protein phosphorylation and IL-2 mRNA degradation. Arginase 1 (Arg1) together with iNOS consume extracellular L-arginine which inhibits CD3 ζ-chain expression interfering with TCR signaling. Arg1 produces L-ornithine that is the substrate of polyamines linked to proliferation and collagen involved in tissue repair and fibrosis. Cyclooxygenase 2 (COX-2) and microsomal prostaglandin E2 synthase (mPGES-1) produce suppressive prostaglandin E2 (PGE2). Indoleamine 2,3-Dioxygenase (IDO) converts L-tryptophan into L-kynurenine which also blocks T cell proliferation. On the other hand, the SLAMF1 receptor interacting with T. cruzi can trigger the conversion of PI to PI3P activating NOX-2 through the EAT2 adaptor. We observed that nfection by the parasite causes depletion of L-arginine levels, which inhibits T-cell proliferation and RNS including nitric oxide (NO) by iNOS. L-arginine supplementation in infected mice produced a decrease in mortality and an improvement in the clinical score of the mice, which could be used in combined therapy. Furthermore, the immune receptor SLAMF1, regulator of the production of reactive oxygen species (ROS), inhibits ROS production in a strain-dependent manner, so that inhibition of the interaction of SLAMF1 with the parasite could be the basis for a new therapy. Our interest in the translational application of our research leads us maintain scientific collaborations with Spanish and foreign groups, basic and clinical, for the evaluation of new prognostic and follow-up biomarkers, needed for deciding treatment of patients and its efficacy. For this, we use “Omics” tools as Genomics, Transcriptomics, Proteomics, and Metabolomics.

Image

Figure 1. Main mechanisms of T cell immune suppression mediated by MDSCs and SLAMF1 receptor. Question marks indicate those processes that need to be further explored (from Fresno M, Gironès N. 2021. Front Cell Infect Microbiol. Aug 27;11:737364).

Image


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Gironés PujolNuria126/114.34593/4735ngirones(at)cbm.csic.esProfesor Titular Universidad, GA
Santos PeñalozaDiana Karolina1264735Tco. de Investigación y Laboratorio

Relevant publications:

  • Fresno M, Gironès N (AC) (2/2). 2021. Myeloid-Derived Suppressor Cells in Trypanosoma cruzi Front Cell Infect Microbiol. Aug 27;11:737364.
  • Callejas-Hernández F, Herreros-Cabello A, Del Moral-Salmoral J, Fresno M (AC), Gironès N (AC) (5/5). The Complete Mitochondrial DNA of Trypanosoma cruzi: Maxicircles and Minicircles. Front Cell Infect Microbiol. Jun 29;11:672448.
  • Herreros-Cabello A, Callejas-Hernández F, Gironès N, Fresno M (3/4). Trypanosoma cruziGenome: Organization, Multi-Gene Families, Transcription, and Biological Implications. Genes (Basel). Oct 14;11(10):1196.
  • Poveda C, Herreros-Cabello A, Callejas-Hernández F, Osuna-Pérez J, Maza MC, Chillón-Marinas C, Calderón J, Stamatakis K, Fresno M, Gironès N. 2020. Interaction of Signaling Lymphocytic Activation Molecule Family 1 (SLAMF1) receptor with Trypanosoma cruzi is strain-dependent and affects NADPH oxidase expression and activity. PLoS Negl Trop Dis. Sep 14;14(9):e0008608.
  • Callejas-Hernández F, Gutiérrez-Nogués Á, Rastrojo A, Gironès N, Fresno M. 2019. Analysis of mRNA processing at whole transcriptome level, transcriptomic profile and genome sequence refinement of Trypanosoma cruzi. Sci Rep. Nov 22;9(1):17376.
  • Herreros-Cabello A, Callejas-Hernández F, Fresno M, Gironès N. 2019. Comparative proteomic analysis of trypomastigotes from Trypanosoma cruzi strains with different pathogenicity. Infect Genet Evol. Dec;76:104041.
  • Callejas-Hernández C, Rastrojo A, Poveda C, Gironès N and Fresno M. 2018. Genomic assemblies of newly sequenced Trypanosoma cruzi strains reveal new genomic expansion and greater complexity. Sci Rep. Oct 2; 8:14631.
  • Carbajosa S, Rodríguez-Angulo HO, Gea S, Chillón-Marinas C, Poveda C, Maza MC, Colombet D, Fresno M, Gironès N. L-arginine supplementation reduces mortality and improves disease outcome in mice infected with Trypanosoma cruzi. PLoS Negl Trop Dis. 2018 Jan 16;12(1):e0006179.
  • Cuervo H, Guerrero NA, Carbajosa S, Beschin A, De Baetselier P, Gironès N, Fresno M. Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection. J Immunol. 2011 Sep 1;187(5):2656-65. doi: 10.4049/jimmunol.1002928. Epub 2011 Jul 29. PMID: 21804013.
  • Cuervo H, Pineda MA, Aoki MP, Gea S, Fresno M, Gironès N. Inducible nitric oxide synthase and arginase expression in heart tissue during acute Trypanosoma cruzi infection in mice: arginase I is expressed in infiltrating CD68+ macrophages. J Infect Dis. 2008 Jun 15;197(12):1772-82.

corresponding author. 1 equal contribution to the direction of the work

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers:

fondosocialeuropeo-300px.png
Ministerio-de-Ciencia-e-Innovacin-600px.png
Comunidad-de-Madrid-600Bpx.png
agenda20-30-600px.png
fundacion-areces600px0710.png
LOGO_ERC.jpg
hrexcellence.jpg
worldwidecancerresearch-600px0710.png
aecc-600tpx.png
bbva-fund-400.png
Niemann-Pick-400px.png
wilderfund-400px.png
AliciaKoplowitz-400px.png
la-caixa-fund-600px.png
inocente-inocente-600px.png
cure-alzheimers-fund-600px.png
citrin-foundation.png
tatiana-fund02-600bpx1.png
campus-excelencia-600x400px.png
fundacion-uno-entre-cien-mil-v02.png